Adverum Biotechnologies Inc (ADVM)

01:05 AM

Adverum Biotechnologies (NASDAQ:ADVM) versus Metagenomi (NASDAQ:MGX) Head-To-Head Analysis - Defense World

01:05 AM

Jun 05, 2025

Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jun 05, 2025

Jun 05, 2025

Adverum Awards 14,610 Shares in Stock Options and RSUs to Key New Hires - Stock Titan

Jun 05, 2025

May 16, 2025

Adverum Biotechnologies Reports Q1 2025 Financial Results - TipRanks

May 16, 2025

May 15, 2025

Adverum Biotechnologies (ADVM) Sees Price Target Adjustment by RBC Capital | ADVM Stock News - GuruFocus

May 15, 2025

May 15, 2025

Adverum Biotechnologies (ADVM) Receives Continued Buy Rating from Chardan Capital | ADVM Stock News - GuruFocus

May 15, 2025

May 15, 2025

Adverum Biotechnologies (ADVM) Price Target Reduced by RBC Capit - GuruFocus

May 15, 2025

May 15, 2025

Adverum Biotechnologies (ADVM) Rating Reiterated at 'Buy' by HC Wainwright | ADVM Stock News - GuruFocus

May 15, 2025

May 15, 2025

RBC Cuts Price Target on Adverum Biotechnologies to $4 From $5, Keeps Sector Perform, Speculative Risk - marketscreener.com

May 15, 2025

May 15, 2025

Adverum Biotechnologies: Q1 Earnings Snapshot - CT Insider

May 15, 2025

May 14, 2025

Adverum (ADVM) Projects Funding Through Late 2025 | ADVM Stock N - GuruFocus

May 14, 2025

May 14, 2025

Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights - The Manila Times

May 14, 2025

May 14, 2025

Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline ... - Bluefield Daily Telegraph

May 14, 2025

May 14, 2025

Revolutionary One-Time Gene Therapy Shows 3.5-Year Vision Protection in Wet AMD Patients - Stock Titan

May 14, 2025

May 07, 2025

Adverum Biotechnologies Inc (ADVM)’s Market Momentum: Closing Strong at 3.23, Down -10.03 - DWinneX

May 07, 2025

May 07, 2025

Adverum Biotechnologies’ SWOT analysis: gene therapy firm faces pivotal year - Investing.com Nigeria

May 07, 2025

May 06, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc.ADVM - PR Newswire

May 06, 2025

May 06, 2025

Adverum Biotechnologies' SWOT analysis: gene therapy firm faces pivotal year - Investing.com

May 06, 2025

May 05, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum ... - Bluefield Daily Telegraph

May 05, 2025

May 05, 2025

Adverum Biotechnologies Inc expected to post a loss of $1.94 a shareEarnings Preview - TradingView

May 05, 2025

May 02, 2025

Adverum Biotechnologies Awards Strategic Stock Options Worth $108,000 to Expand Team - Stock Titan

May 02, 2025

May 02, 2025

It makes sense and dollars to buy Adverum Biotechnologies Inc (ADVM) stock - Sete News

May 02, 2025

Apr 30, 2025

Adverum Biotechnologies Inc: Navigating Market Volatility with a 1.79 Debt-to-Equity Ratio - investchronicle.com

Apr 30, 2025

Apr 28, 2025

Adverum Biotechnologies Inc [ADVM] Investment Guide: What You Need to Know - knoxdaily.com

Apr 28, 2025

Apr 28, 2025

Should investors be concerned about Adverum Biotechnologies Inc (ADVM)? - uspostnews.com

Apr 28, 2025

Apr 28, 2025

Gaining Ground: Adverum Biotechnologies Inc (ADVM) Closes Lower at 2.91, Down -2.02 - DWinneX

Apr 28, 2025

Apr 26, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 26, 2025

Apr 24, 2025

Hedge Fund and Insider Trading News: Ken Griffin, Steve Cohen, Scott Bessent, Balyasny Asset Management, Bridgewater Associates, Starboard Value, Maverick Capital, Kodai Capital Management, Antara Capital, Adverum Biotechnologies Inc (ADVM), and - Insider Monkey

Apr 24, 2025

Apr 24, 2025

Adverum Biotechnologies Insider Bought Shares Worth $1,048,950, According to a Recent SEC Filing - marketscreener.com

Apr 24, 2025

Apr 24, 2025

Adverum Biotechnologies Insider Buys 350,000 Shares - TradingView

Apr 24, 2025

Apr 23, 2025

Adverum Biotechnologies Inc (ADVM) is an excellent investment, but the stock is overvalued/undervalued right now - uspostnews.com

Apr 23, 2025

Apr 23, 2025

Trading Day Triumph: Adverum Biotechnologies Inc (ADVM) Ends at 2.96, a 8.42 Surge/Plunge - DWinneX

Apr 23, 2025

Apr 21, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Adverum Biotechnologies, Inc. (ADVM) Stockholders to Inquire about Securities Investigation - markets.businessinsider.com

Apr 21, 2025

Apr 21, 2025

Truist Removes $40 Price Target on Adverum Biotechnologies, Cites Share Volatility, Keeps Buy Rating - marketscreener.com

Apr 21, 2025

Apr 20, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Adverum Biotechnologies, Inc. (ADVM) Investors to Inquire about Securities Investigation - markets.businessinsider.com

Apr 20, 2025

Apr 18, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Adverum Biotechnologies, Inc. (ADVM) And Encourages Investors to Reach Out - markets.businessinsider.com

Apr 18, 2025

Apr 18, 2025

Adverum Biotechnologies (NASDAQ:ADVM) Earns Buy Rating from HC Wainwright - Defense World

Apr 18, 2025

Apr 17, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Adverum Biotechnologies, Inc. (ADVM) And Encourages Stockholders to Reach Out - markets.businessinsider.com

Apr 17, 2025

Apr 17, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - GlobeNewswire Inc.

Apr 17, 2025

Apr 17, 2025

Intuit To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga

Apr 17, 2025

Apr 16, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Adverum Biotechnologies, Inc. (ADVM) And Encourages Stockholders to Connect - markets.businessinsider.com

Apr 16, 2025

Apr 16, 2025

RBC Cuts Price Target on Adverum Biotechnologies to $5 From $10, Keeps Sector Perform, Speculative Risk - marketscreener.com

Apr 16, 2025

Apr 15, 2025

Adverum Biotechnologies Reports 2024 Financial Results and Pipeline Progress - TipRanks

Apr 15, 2025